Evonik is transforming its health care business to prioritise customer centricity and market focus, the company says. Effective April 1, 2022, the company will streamline its operations into three distinct product lines: drug delivery & product, drug substance, and health solutions. Each product line builds on core competencies and differentiating technology platforms to meet the specific requirements of diverse healthcare markets.
This structural shift is aimed to further transitions the health care business line into a system solutions partner for the pharmaceutical and biotech industries.
“This strategic transformation of our business line will unleash innovation and new service potential – for the benefit of our customers and patients. We’re proud to be the preferred development and manufacturing partner for the industry’s most innovative therapies,” said Dr Thomas Riermeier, head of Evonik’s health care business line.
The drug delivery & products unit, headed by Paul Spencer, will focus on advancing the company’s system solutions for advanced oral and parenteral drug delivery. This includes the portfolio of excipients, lipids, and lipid nanoparticles (LNPs), with complementary CDMO services from feasibility studies to commercial drug products.
The recently added drug substance unit encompasses the company’s custom development and manufacturing organisation (CDMO) services for APIs and intermediates as well as its portfolio of API products. Building on facilities in the US and Germany, the company supports customers with scale-up from clinical phases to commercial production, including large-scale high potency APIs (HPAPI) and multi-step complex APIs. This unit is led by Dr Stefan Randl.
Under the leadership of Maximillian Yeh, the health solutions product line will focus on fast-growing markets. The unit brings together the biopharma, medical device, and advanced food ingredients businesses.
